718 related articles for article (PubMed ID: 28886696)
21. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
22. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
23. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Wilkerson PM; Dedes KJ; Samartzis EP; Dedes I; Lambros MB; Natrajan R; Gauthier A; Piscuoglio S; Töpfer C; Vukovic V; Daley F; Weigelt B; Reis-Filho JS
Oncotarget; 2017 Jan; 8(4):6057-6066. PubMed ID: 28002809
[TBL] [Abstract][Full Text] [Related]
26. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
27. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
28. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
[TBL] [Abstract][Full Text] [Related]
29. [Targeting Ras-PI3K/mTOR pathway and the predictive biomarkers in endometrial cancer].
Oda K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1084-7. PubMed ID: 21772091
[TBL] [Abstract][Full Text] [Related]
30. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
31. PI3K p110α inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
Cao P; Wang Y; Lv Y; Jiang N; Zhong L; Ma X; Xiao X; Ding D; Gu J; Lin L; Li S
Oncol Rep; 2019 Nov; 42(5):2097-2107. PubMed ID: 31545455
[TBL] [Abstract][Full Text] [Related]
32. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
33. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
34. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
35. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
36. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Yang L; Yang G; Ding Y; Huang Y; Liu S; Zhou L; Wei W; Wang J; Hu G
Oncol Rep; 2018 Jul; 40(1):479-487. PubMed ID: 29767248
[TBL] [Abstract][Full Text] [Related]
38. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
[TBL] [Abstract][Full Text] [Related]
39. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
[TBL] [Abstract][Full Text] [Related]
40. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
